Corium International, Inc.
Corium International, Inc. (CORI): 9 pipeline candidates · ~27 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
27.0 months
D/E 3.50 · 0% dilution
Lead: Phase 3
9 candidates
N/A
N/A
A transparent, data-derived signal for Corium International, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$82.5M
Quarterly Burn
$9.4M
Runway
27.0 mo
Revenue
$7.7M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (9 candidates)
| Drug | Phase |
|---|---|
| aripiprazole tds | Phase 1 |
| corplex donepezil | Phase 3 |
| corplex memantine | Phase 1 |
| donepezil tds | Phase 1 |
| memantine tds | Phase 1 |
| microcor hpth | Phase 2 |
| ropinirole tds | Preclinical |
| serdexmethylphenidate | Phase 4 |
| twirla | Phase 3 |
Frequently asked questions
How many drug candidates are in Corium International, Inc.'s pipeline?
Corium International, Inc. (CORI) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Corium International, Inc.'s lead drug candidate?
Corium International, Inc.'s most advanced tracked candidate is aripiprazole tds (Phase 1) for Psychiatric Disorders.
What is Corium International, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Corium International, Inc. has approximately 27.0 months of cash runway.
Who is the CEO of Corium International, Inc.?
California January is the chief executive officer of Corium International, Inc. (CORI).
Get the full picture on Corium International, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.